HMN 2026: How Radiopharmaceutical may benefit patients with metastatic prostate cancer sooner
Health Medicine Network,
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a…
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Overview of attention for article published in The Lancet, August 2026
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (91st percentile)
Readers on
- mendeley
- 4 Mendeley